Kymera Therapeutics, Inc., together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, which are in Phase I and IND-enabling respectively. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kiniksa Pharmaceuticals (KNSA), Kymera Therapeutics ...

Analysts Are Bullish on These Healthcare Stocks: Kiniksa Pharmaceuticals (KNSA), Kymera Therapeutics (KYMR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Bicycle Therapeutics (BCYC), Kymera Therapeutics (...

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC), Kymera Therapeutics (KYMR) and Teleflex (TFX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tenet Healthcare (THC) and Kymera Therapeutics (KYMR...

Analysts Offer Insights on Healthcare Companies: Tenet Healthcare (THC) and Kymera Therapeutics (KYMR)

In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on Kymera Therapeutics, with a price target of $120.00. The company...

Kymera Therapeutics (KYMR) Gets a Buy from Citi

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Kymera Therapeutics, with a price target of $133.00. According to...

Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Axsome Therapeutics (AXSM) and Kymera Therapeutics (...

Market Cap	$6.43B	P/E Ratio	N/A
52W High	$103.00	52W Low	$28.06
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-8.7%	52W Position	69.2%
Overall Score	56	Value Score	55
Quality Score	55	Technical Score	60

EPS Current Est	$-3.34	EPS Next Est	$-4.2
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KYMR	$79.94	+1.33%	289.61K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KYMR	$79.94	+1.3%	289.61K
3
4
5
6

KYMR

KYMR

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Kymera Therapeutics Inc. Data in Excel

Get Kymera Therapeutics Inc. Data in Excel